Pemigatinib for Cholangiocarcinoma– A Novel Drug
Oncology-Pemigatinib
DOI:
https://doi.org/10.22376/ijtos.2023.1.4.31-37Keywords:
Cholangiocarcinoma, Pemigatinib, Fibroblast Growth Factor Receptor, Bile duct cancer, Intrahepatic cholangiocarcinoma, PEMAZYRE TMAbstract
Cholangiocarcinoma(CLCA) is a cancer that develops in the narrow tubes known as bile ducts, which transport the digesting fluid bile. This disease, also recognized as Hepatic-duct cancer, is a form of tumor that is extremely difficult to cure with standard chemotherapy. iCLCA refers to cancers that develop within the gastrointestinal tract of the Hepatic-ducts inside the liver and are usually instigated by mutations in the Fibroblast Growth Factor Receptor2 (FiGFR2) gene. Pemigatinib(Pg) is a distinctive, powerful medication that specifically inhibits the action of mutated FGFR2 and is now identified being a viable therapy option for individuals with intrahepatic CLCA. Cholangiocarcinoma (CLCA) is a diverse category of cancers with few therapeutic options. Considering the latest developments in health oncology, CLCA individuals with metastasizing cancer have a terrible prognosis, with an overall median lifespan of barely an entire year. The CLCA health community has made substantial efforts in the recent decade to enhance distinct clinical results by introducing molecularly embattled treatments in this environment. Among some of these therapies, the FiGFR 2 inhibitor Pg has been granted rapid authorization by the USA-Food and Drug Administration (FDA) in CLCA individuals who have FiGFR2 gene combinations or additional rearrangements founded on the outcomes of the FIGHT-202 trial, making it the initial molecularly specific rehabilitation to be endorsed as a remedy of CLCA.This review seeks to present a concise review of pemigatinib's latest advancement, with a precise emphasis on the FIGHT-202 study, the endorsement of this FiGFR inhibitor, and the impending problems related to the routine of FiGFR-directed medicines in CLCA individuals.
References
Katabathina VS, Khanna L, Surabhi VR, Minervini M, Shanbhogue K, Dasyam AK, Prasad SR. Morphomolecular classification update on hepatocellular adenoma, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma. Radiographics. 2022 Sep;42(5):1338-57.
Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2, 10 (2002).
Ross JS, Wang K, Gay L et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 19(3), 235–242 (2014).
Graham RP, Barr Fritcher EG, Pestova E et al.Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum. Pathol. 45(8), 1630–1638 (2014).
Merz V, Zecchetto C, Melisi D. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future oncology. 2020 Sep;17(4):389-402.
Franco B, Clarke P, Carotenuto P. Pemigatinib. Fibroblast growth factor receptor inhibitor, Treatment of cholangiocarcinoma. Drugs of the Future. 2019 Dec 1;44(12).
Spanggaard I, Matrana M, Rocha-Lima C, Mahipal A, Vieito M, Hervieu A, Ahn MJ, Goyal L, Ahnert JR, Veronese L, Oliveira N. PemigatinibFor Previously Treated Central Nervous System Tumors With Activating FGFR Mutations or Translocations: Results From FIGHT-207 (S17. 004).
Drilon A, Sharma MR, Johnson ML, Yap TA, Gadgeel S, Nepert D, Feng G, Reddy MB, Harney AS, Elsayed M, Cook AW. SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. Cancer Discovery. 2023 Jun 3:OF1-3.
Pace A, Scirocchi F, Napoletano C, Zizzari IG, Po A, Megiorni F, Asquino A, Pontecorvi P, Rahimi H, Marchese C, Ferretti E. Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor miRNAs.
Umemoto K, Yamamoto H, Oikawa R, Izawa MD, Moore JA, Sokol ES, Sunakawa Y, Sunakawa Y. The molecular landscape of pancreatobiliary cancers for novel targeted therapies.
Freyer CW, Hughes ME, Carulli A, Bagg A, Hexner E. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement. Expert Review of Anticancer Therapy. 2023 Apr 3;23(4):351-9.
Kumar S, Gupta H. Recent Development of Anticancer Agents. pathophysiology. 2022;10:11.
Szklener K, Chmiel P, Michalski A. Ma ndziuk, S. New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors. Cancers 2022, 14, 1416.
Spanggaard I, Matrana M, Rocha-Lima C, Mahipal A, Vieito M, Hervieu A, Ahn MJ, Goyal L, Ahnert JR, Veronese L, Oliveira N. PemigatinibFor Previously Treated Central Nervous System Tumors With Activating FGFR Mutations or Translocations: Results From FIGHT-207 (S17. 004).
Lamarca A, Palmer DH, Wasan HS et al. ABC-06 | A randomised Phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/ 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J. Clin. Oncol. 37(Suppl. 15), 4003–4003 (2019).
Abou-Alfa GK, Sahai V, Hollebecque A et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, Phase II study. Lancet Oncol. 21(5), 671–684 (2020).
Patel TH, Marcus L, Horiba MN, Donoghue M, Chatterjee S, Mishra-Kalyani PS, Schuck RN, Li Y, Zhang X, FourieZirkelbach J, Charlab R. FDA approval summary: Pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement. Clinical Cancer Research. 2023 Mar 1;29(5):838-42.
Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 17(5), 318–332 (2017).
Baldo BA. Immune-and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies. Antibodies 2022, 11, 17.
Beri N. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. Future Oncology. 2022 Apr;18(11):1391-402.
Lenherr-Taube N, Furman M, Assor E, Thummel K, Levine MA, Sochett E. Rifampin monotherapy for children with idiopathic infantile hypercalcemia. The Journal of Steroid Biochemistry and Molecular Biology. 2023 Jul 1;231:106301.
Paiva B, Manrique I, Dimopoulos MA, Gay F, Min CK, Zweegman S, Špička I, Teipel R, Mateos MV, Giuliani N, Cavo M. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and-MM4 trials. Blood, The Journal of the American Society of Hematology. 2023 Feb 9;141(6):579-91.
Kim SM, Kim H, Yun MR et al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis5(7), e241 (2016).
Javle M, Lowery M, Shroff RT et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J. Clin. Oncol. 36(3), 276–282 (2018).
De SK. Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer. Current Medicinal Chemistry. 2023.
Balasubramanian B, Yacqub-Usman K, Venkatraman S, Myint KZ, Juengsamarn J, Sarkhampee P, Lertsawatvicha N, Sripa J, Kuakpaetoon T, Suriyonplengsaeng C, Wongprasert K. Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma. Cancers. 2023 Apr 28;15(9):2528.
Tsimafeyeu I, Statsenko G, Vladimirova L, Besova N, Artamonova E, Raskin G, Rykov I, Mochalova A, Utyashev I, Gorbacheva S, Kazey V. A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer. Investigational New Drugs. 2023 Apr;41(2):324-32.
Tripathi A, MacDougall K, Sonpavde GP. Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint. Drugs. 2022 Nov;82(17):1649-62.
Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies. Expert Review of Precision Medicine and Drug Development. 2022 Jan 2;7(1):102-4.
Liu PCC, Koblish H, Wu L, et al. INCB054828 (pemigatinib), apotent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS One. 2020;15(4):e0231877.
Mahapatra S, Jonniya NA, Koirala S, Ursal KD, Kar P. The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention. Journal of Biomolecular Structure and Dynamics. 2023 Mar 16:1-25.
Javle M, King G, Spencer K, Borad MJ. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors. The Oncologist. 2023 Jun 30:oyad149.
Incyte Corporation. PEMAZYRE™ (pemigatinib) tablets, for oral use: US prescribing information. 2020. https://www.fda.gov/.Accessed 28 Apr 2020.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Kiruthika Balasubramanian, Dr Bablee Jyoti, Vinoth Kumar S, Dr Ammar A. Razzak Mahmood, M Thillainayagi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
